Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
CNTA Centessa Pharmaceuticals
3.760+0.040+1.08%
Trading Session
02/08 12:00 ET
High
3.790
Open
3.610
Turnover
74.00K
Low
3.610
Pre Close
3.720
Volume
19.88K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Centessa Pharmaceuticals to Present Additional Data From Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
BOSTON and LONDON, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transfo
Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference
BOSTON and LONDON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are tra
Centessa Pharma Get FDA Nod to Begin Trial of Solid Tumors Treatment
Street Color: Centessa Pharmaceuticals Receives US FDA Approval to Start Phase 1/2a Trial of Solid Tumors Therapy
11:37 AM EST, 01/26/2023 (MT Newswires) -- (Street Color news is derived from real time discussions with market professionals globally subscribed to the Street Color Premium Chat service on Bloomberg
Centessa Pharmaceuticals Gets FDA Clearance for LB101 Clinical Trial
By Chris Wack Centessa Pharmaceuticals Plc said Thursday that it has received clearance for its Investigational New Drug application from the U.S. Food and Drug Administration to initiate a Phase 1/2
Centessa Announces FDA Clearance of IND to Initiate Phase 1/2a Study of LB101
Centessa Pharmaceuticals Announces FDA Clearance Of IND Application For Phase 1/2a Clinical Trial Of LB101, First LockBody Candidate, For Solid Tumors
Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has rece
Morgan Stanley Adjusts Price Target on Centessa Pharmaceuticals to $4 From $5, Maintains Underweight Rating
10:32 AM EST, 01/24/2023 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Centessa Pharmaceuticals Price Target Cut to $4.00/Share From $5.00 by Morgan Stanley
Centessa Pharmaceuticals Price Target Cut to $4.00/Share From $5.00 by Morgan Stanley
Centessa Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/24/2023 3.36% Morgan Stanley $5 → $4 Maintains Underweight 08/12/2022 29.2% Morgan Stanley $10 → $5 Dow
Company Overview
More
Centessa Pharmaceuticals Ltd. operates as pharmaceutical company that develops medicines. The company was founded on October 26, 2020 and is headquartered in Cambridge, the United Kingdom.
CEO： Mr. Saurabh Saha
Market： NASDAQ
Listing Date： 05/28/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet